Healthcare provider profile · identity verified

Karen Mcdaniel, ARNP

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MIDDLESBORO, KY · NPI 1144278631

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Karen Mcdaniel, ARNP received $27.86 in general payments during 2025 across 2 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 51.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$27.86

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$14.23	51.1%	1	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$13.63	48.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$27.86	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$14.23	1	2025
Source payment records 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.23 · Open Payments source
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$13.63	1	2025
Source payment records 2025-07-10 · Lilly USA, LLC · $13.63 · Open Payments source
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$13.63	1	2025
Source payment records 2025-07-10 · Lilly USA, LLC · $13.63 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
MOUNJARO mounjaro	2025	Mounjaro	2024	21 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	205	31
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	51	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	778	114
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	571	80
Amlodipine Besylate	Amlodipine Besylate	531	89
Atorvastatin Calcium	Atorvastatin Calcium	478	87
Losartan Potassium	Losartan Potassium	462	71
Famotidine	Famotidine	444	76
Rosuvastatin Calcium	Rosuvastatin Calcium	418	67
Metformin Hcl	Metformin Hcl	345	59
Gabapentin	Gabapentin	291	48
Atenolol	Atenolol	277	37
Lisinopril	Lisinopril	276	45
Potassium Chloride	Potassium Chloride	271	54
Montelukast Sodium	Montelukast Sodium	265	40
Furosemide	Furosemide	256	47
Alprazolam	Alprazolam	253	37
Escitalopram Oxalate	Escitalopram Oxalate	253	35
Simvastatin	Simvastatin	209	34
Januvia	Sitagliptin Phosphate	205	28
Jardiance	Empagliflozin	205	31
Benazepril Hcl	Benazepril Hcl	177	23
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	175	35
Alendronate Sodium	Alendronate Sodium	174	33
Omeprazole	Omeprazole	171	30
Metoprolol Tartrate	Metoprolol Tartrate	168	32
Diazepam	Diazepam	157	22
Metoprolol Succinate	Metoprolol Succinate	153	29
Azithromycin	Azithromycin	144	89
Clopidogrel	Clopidogrel Bisulfate	141	22
Ventolin Hfa	Albuterol Sulfate	141	25
Hydralazine Hcl	Hydralazine Hcl	131	21
Sertraline Hcl	Sertraline Hcl	130	23
Tramadol Hcl	Tramadol Hcl	127	26
Albuterol Sulfate Hfa	Albuterol Sulfate	124	37
Pantoprazole Sodium	Pantoprazole Sodium	123	24
Fluticasone Propionate	Fluticasone Propionate	121	40
Allopurinol	Allopurinol	120	20
Isosorbide Mononitrate Er	Isosorbide Mononitrate	120	17
Methylprednisolone	Methylprednisolone	118	76
Spironolactone	Spironolactone	109	25
Clonazepam	Clonazepam	108	19
Pregabalin	Pregabalin	104	18
Trazodone Hcl	Trazodone Hcl	98	15
Hydrochlorothiazide	Hydrochlorothiazide	96	22
Quetiapine Fumarate	Quetiapine Fumarate	96	13
Eliquis	Apixaban	95	14
Farxiga	Dapagliflozin Propanediol	95	18
Diclofenac Sodium	Diclofenac Sodium	83	35
Glipizide	Glipizide	81	14
Tamsulosin Hcl	Tamsulosin Hcl	81	15
Carvedilol	Carvedilol	80	15
Ezetimibe	Ezetimibe	80	11
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	79	15
Doxycycline Hyclate	Doxycycline Hyclate	78	58
Nystatin	Nystatin	74	22
Fluoxetine Hcl	Fluoxetine Hcl	72	11
Glimepiride	Glimepiride	72	suppressed
Pravastatin Sodium	Pravastatin Sodium	69	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	69	26
Promethazine Hcl	Promethazine Hcl	68	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	67	12
Citalopram Hbr	Citalopram Hydrobromide	65	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	65	12
Amitriptyline Hcl	Amitriptyline Hcl	63	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	63	suppressed
Meclizine Hcl	Meclizine Hcl	61	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	59	17
Meloxicam	Meloxicam	58	15
Sucralfate	Sucralfate	58	14
Ibuprofen	Ibuprofen	56	16
Donepezil Hcl	Donepezil Hcl	52	12
Valsartan	Valsartan	52	suppressed
Trulicity	Dulaglutide	51	suppressed
Fluconazole	Fluconazole	50	22
Folic Acid	Folic Acid	50	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	50	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	48	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	48	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	46	suppressed
Prednisone	Prednisone	46	16
Cilostazol	Cilostazol	44	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	44	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	44	suppressed
Buspirone Hcl	Buspirone Hcl	43	suppressed
Warfarin Sodium	Warfarin Sodium	42	suppressed
Nebivolol Hcl	Nebivolol Hcl	41	suppressed
Ondansetron Hcl	Ondansetron Hcl	39	11
Tizanidine Hcl	Tizanidine Hcl	39	suppressed
Baclofen	Baclofen	37	suppressed
Ampicillin Trihydrate	Ampicillin Trihydrate	36	28
Ciprofloxacin Hcl	Ciprofloxacin Hcl	36	31
Levofloxacin	Levofloxacin	36	31
Cefdinir	Cefdinir	35	34
Combivent Respimat	Ipratropium/Albuterol Sulfate	35	suppressed
Lorazepam	Lorazepam	35	suppressed
Ozempic	Semaglutide	35	suppressed
Phenobarbital	Phenobarbital	35	suppressed
Azelastine Hcl	Azelastine Hcl	34	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	34	26
Vascepa	Icosapent Ethyl	34	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	32	24
Breo Ellipta	Fluticasone/Vilanterol	32	suppressed
Celecoxib	Celecoxib	31	suppressed
Synthroid	Levothyroxine Sodium	31	suppressed
Olanzapine	Olanzapine	30	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	28	suppressed
Dexlansoprazole Dr	Dexlansoprazole	27	suppressed
Lansoprazole	Lansoprazole	26	suppressed
Topiramate	Topiramate	26	suppressed
Bupropion Hcl	Bupropion Hcl	25	suppressed
Donepezil Hcl Odt	Donepezil Hcl	25	suppressed
Tradjenta	Linagliptin	25	suppressed
Estradiol	Estradiol	24	suppressed
Mirtazapine	Mirtazapine	24	suppressed
Eszopiclone	Eszopiclone	23	suppressed
Mupirocin	Mupirocin	23	15
Nitroglycerin	Nitroglycerin	23	suppressed
Xarelto	Rivaroxaban	23	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Memantine Hcl	Memantine Hcl	22	suppressed
Ranolazine Er	Ranolazine	22	suppressed
Valacyclovir	Valacyclovir Hcl	22	12
Clonidine Hcl	Clonidine Hcl	21	suppressed
Colchicine	Colchicine	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	21	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	21	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Mounjaro	Tirzepatide	21	suppressed
Cephalexin	Cephalexin	20	15
Isosorbide Dinitrate	Isosorbide Dinitrate	20	suppressed
Methocarbamol	Methocarbamol	20	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	20	suppressed
Bupropion Hcl Sr	Bupropion Hcl	19	suppressed
Finasteride	Finasteride	19	suppressed
Verapamil Er	Verapamil Hcl	19	suppressed
Clobetasol Propionate	Clobetasol Propionate	18	suppressed
Hydrocortisone	Hydrocortisone	18	suppressed
Ketoconazole	Ketoconazole	18	suppressed
Metformin Hcl Er	Metformin Hcl	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Doxepin Hcl	Doxepin Hcl	17	suppressed
Duloxetine Hcl	Duloxetine Hcl	17	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	17	suppressed
Brilinta	Ticagrelor	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Steglatro	Ertugliflozin Pidolate	16	suppressed
Temazepam	Temazepam	16	suppressed
Carbamazepine Er	Carbamazepine	15	suppressed
Gemfibrozil	Gemfibrozil	15	suppressed
Linzess	Linaclotide	15	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	15	15
Ramipril	Ramipril	15	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	13	suppressed
Bumetanide	Bumetanide	12	suppressed
Epinephrine	Epinephrine	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Methotrexate	Methotrexate Sodium	12	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	12	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Verapamil Hcl	Verapamil Hcl	12	suppressed
Belsomra	Suvorexant	11	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	11	suppressed
Cefuroxime	Cefuroxime Axetil	11	suppressed
Divalproex Sodium	Divalproex Sodium	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	11	suppressed
Pen Needles	Pen Needle, Diabetic	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Synjardy Xr	Empagliflozin/Metformin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$27.86 · 2 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	CAPLYTA, MOUNJARO, ZEPBOUND	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Mounjaro play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error